Joseph Powell will discuss how heterogeneous subpopulations of HPV+ head and neck cancer cells drive unique disease states, cell-cell interactions, and microenvironment dynamics, and have implications for cancer behavior, metastasis, and response to treatment.   

Researchers use a new way to deliver CRISPR/Cas9 to tumors in mice, wiping out the cancer.

The Johns Hopkins University researcher’s work helped solidify the link between human papillomavirus and cervical cancer, leading to the approval of the HPV vaccine in 2006.

SHERLOCK and DETECTR can identify particular nucleic acid sequences, while CAMERA records events in human and bacterial cells.

Douglas Lowy and John Schiller, whose work led to the HPV vaccine, and Michael Hall, who discovered the TOR pathway, win this year’s prizes.

Oncologists have raised concerns about a mouse study that suggests the vaccine for human papillomavirus could cause brain damage.

The editor in chief of Vaccine has “temporarily removed” a study, published on the journal’s website in January, which suggested the aluminum adjuvant in an HPV vaccine caused behavioral changes in mice.

The US Food and Drug Administration approves a cervical test for human papillomavirus to be used as a primary cancer screening tool.

In contrast to yesterday’s news about the success of an HPV vaccine program in Australia, an Indian trial of the vaccine is stoking unfounded fear among the public and exposing some questionable ethical standards.

An HPV vaccination program in Australia appears to have resulted in a drop in cervical lesions among young women.